We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulmonary Vein Isolation Outcomes With Fish Oils (PUFA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00841451
Recruitment Status : No longer available
First Posted : February 11, 2009
Last Update Posted : March 23, 2016
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
St. Luke's-Roosevelt Hospital Center

February 10, 2009
February 11, 2009
March 23, 2016
 
Pulmonary Vein Isolation Outcomes With Fish Oils
Fish oil therapy may decrease the incidence of cardiac arrhythmias. This study will test whether pre-treatment with fish oils before catheter ablation of atrial fibrillation decreases the early post operative occurrence of atrial fibrillation.
Not Provided
Expanded Access
Drug: Lovaza (Fish Oils)
Double blinded placebo controlled
Other Names:
  • Lovaza NDA021654
  • Omacor NDA021853
Not Provided
 
No longer available
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00841451
St. Luke's-Roosevelt Hospital Center
St. Luke's-Roosevelt Hospital Center
GlaxoSmithKline
Principal Investigator: Suneet Mittal, MD St. Luke's-Roosevelt Hospital Center
St. Luke's-Roosevelt Hospital Center
March 2016